Investigation Of Ansun Biopharma Dismissed, Company Continues Development Of Therapies For Severe Respiratory Infections

SAN DIEGO, July 27, 2015 /PRNewswire/ -- Ansun BioPharma, Inc., a San Diego-based biotech company, is pleased to announce that an investigation by the United States Attorney's office over the misconduct of the former CEO and CFO has been dismissed.

"We are pleased with the dismissal of the investigation.  With new management in place we have made significant progress with our late stage clinical programs for parainfluenza and influenza," noted Dr. Ronald Moss, CEO of Ansun Biopharma. "We also have developed a pipeline of therapies against other respiratory viruses such as metapneumovirus and eneterovirus68."

"Ansun had a rough patch with its former CEO and CFO, but it's a company that has never given up doing important work here in San Diego developing anti-viral therapies for unmet medical needs," stated Ansun's general counsel, Mikael Havluciyan.  "We were very happy to be able to work with the local U.S. Attorney's Office to help resolve the investigation in a way that made sense not just for the Company, but for the national public welfare as well," explained Mr. Havluciyan.

About Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses.  Ansun BioPharma has two products in late stage clinical development. FluDase^TM is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. ParaDase^TM is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients. ParaDase^TM  has received Fast Track Designation by the U.S. FDA. For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/investigation-of-ansun-biopharma-dismissed-company-continues-development-of-therapies-for-severe-respiratory-infections-300118547.html

SOURCE Ansun BioPharma